Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2017

Posted On March 1, 2017 By OrthoSpineNews In Financial /

WARSAW, Ind., March 1, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2017.

The cash dividend of $0.24 per share will be paid on or about April 28, 2017 to stockholders of record as of the close of business on March 31, 2017. Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

SOURCE Zimmer Biomet Holdings, Inc.

DJO Global Announces Appointment of Bryan McMillan as President, Regeneration

Posted On March 1, 2017 By OrthoSpineNews In Recon, Top Stories /

March 1, 2017

SAN DIEGO–(BUSINESS WIRE)–

DJO Global, Inc., a leading global provider of medical technologies designed to get and keep people moving, today announced the appointment of Bryan McMillan as President Regeneration, effective March 1, 2017.

As President of DJO’s Regeneration business, Mr. McMillan will be responsible for both commercial growth strategies and corporate payor development and reimbursement initiatives. Mr. McMillan will report directly to DJO President and Chief Executive Officer, Brady Shirley.

“We are very excited to announce the appointment of Bryan McMillan as President of our Regeneration Business, Reimbursement, and Payor Development to provide effective, affordable solutions, giving patients and providers the attention they deserve to enhance the continuum of care,” said Brady Shirley, DJO President and Chief Executive Officer. “Throughout his career, Bryan has proven to be an agile leader with an extensive understanding of our specific segment and healthcare economics. We are confident that his ability to thrive in a variety of business environments to reach collective goals will serve DJO Global well in its commitment of being a world class organization.”

Mr. McMillan most recently served as the President of CoorsTek Medical, a position he was appointed to in March of 2014 after completing the successful integration of IMDS (Innovative Medical Device Systems) to the Coors family enterprise. In his role, Mr. McMillan was responsible for all functional areas and strategy for a division of the largest engineered ceramics company worldwide.

From 2010 to 2012, Mr. McMillan served in several key leadership positions at Orthofix International, N.V., culminating in his final role there as President for the Global Spine Business Unit. Prior to Orthofix, Mr. McMillan had a successful nine-year tenure at Stryker Corporation, where he held significant roles of increased responsibility, ultimately being promoted to the position of Vice President, Stryker Finance. In this capacity, Mr. McMillan built, developed and led a cross-divisional entity for Stryker to offer internal financing and strategic sales programs. During the “Great economic recession” and with capital equipment sales down, he led the division to record sales with nearly 30% growth in 2009. A large part of his unprecedented achievements can be attributed to Mr. McMillan’s demonstrated leadership skills, unique business acumen, and ability to transform multi-discipline business strategies into tangible outcomes.

Prior to entering the medical device industry, Mr. McMillan spent nearly ten years in investment management and banking with prestigious firms such as Rauscher Pierce, Everen Securities and CIBC Oppenheimer. Mr. McMillan received a Bachelor’s degree in Political Science and Business with honors from Arizona State University, and successfully completed the Harvard Executive Leadership program and Strategic Marketing Curriculum at the University of Texas, Austin.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, REGEN™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006385/en/

Implanet Announces Grant of the French Patent for Jazz Lock®

Posted On March 1, 2017 By OrthoSpineNews In Regulatory, Spine /

March 1, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–

IMPLANET (IMPL.PA) (IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, announces that the French patent office has granted a patent protecting the JAZZ Lock® implant in France.

A major component of an innovative range of band products for spine surgery, Jazz Lock® is an implant designed to treat degenerative spine disorders, whose global market potential is estimated at over $200 million.

An unrivaled implant, thanks to its locking system requiring no rod fixation, Jazz Lock® allows surgeons to shorten and simplify the surgical procedure by removing multiple steps and implants used in traditional system: locking screws and connecting rods.

Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “Obtaining this patent from the French patent office is the first step in fully protecting our Jazz Lock®, and more particularly, its locking mechanism that is the first of its kind in the market. The protection of this latter element is pivotal, insofar as the majority of our future developments will incorporate this technology. We continue to be extremely rigorous regarding the protection of our current and future innovations.”

Ludovic Lastennet, CEO of Implanet, adds: “We are continuing the strict execution of our development strategy, of which the comprehensive protection of our products is a major component. We have submitted the dossier to various global intellectual property authorities, notably the United States. Since its limited launch last autumn in the United States and Europe, Implanet has sold more than 300 Jazz Lock® implants to treat degenerative spine disorders. The clinical feedback from surgeons has been excellent, including important practical aspects such as ease of use and speed of implementation.”

Next financial press release: 2016 annual results, on March 28, 2017

IMPLANET will participate in the following events:

GES (“Groupement d’étude sur la Scoliose” scoliosis study group), Strasbourg, France, March 9 to 11, 2017
AAOS (American Academy of Orthopedic Surgery), San Diego CA, USA, March 15 to 17, 2017

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228007033/en/

Centric Medical™ Announces Initial Cases for Hammertoe Correction System

Posted On March 1, 2017 By OrthoSpineNews In Extremities /

February 28, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology, announced today that the company has successfully completed initial cases with the Hammertoe Correction System. The innovative system offers a dual threaded design and is inserted between the proximal and middle phalanges so that the opposing threads fixate on the phalangeal canal of the toe and compress the joint.

“Centric Medical’s Hammertoe Correction System is the latest in the rapid evolution of permanent implants to improve the results of hammertoe surgery. This outpatient procedure is quick and the Hammertoe System provides excellent fixation and compression to permanently correct hammertoe deformities. Patients no longer need to have pins sticking out the ends of their toes, eliminating the requirement for follow-up surgery,” said Dr. David Friscia of Eisenhower Medical Center in Rancho Mirage, California.

The Hammertoe Correction System is scheduled for a limited release in Q2 of 2017. The initial case follows the news of FDA clearance of Centric Medical’s Metatarsal Hemi Implant. These systems are part of a growing portfolio which includes innovative osteobiologic products, as well as the groundbreaking TARSA-LINK^™ Stand-Alone Wedge Fixation System, the market’s first stand-alone osteotomy wedge with built-in fixation. The system was released to the market in September 2016.

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois.

Contacts

Life Spine, Inc.
Mr. Mariusz Knap
Vice President of Marketing
847-884-6117
mknap@lifespine.com

Cesca Therapeutics Strengthens Leadership Team and Board of Directors

Posted On March 1, 2017 By OrthoSpineNews In Biologics /

RANCHO CORDOVA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced that it has appointed Ms. Vivian Liu as its Chief Operating Officer and elected Dr. Russell Medford to its board of directors.

Ms. Vivian Liu, a member of Cesca’s board of directors since November 2016, has over 20 years of experience in finance, operations and M&A activities for private and public pharmaceutical companies. Prior to joining Cesca, Ms. Liu was the Managing Director of OxOnc Services Company, an oncology product development company. From 1994-2010, she served in various executive roles at NexMed, Inc., which she co-founded and was later renamed Apricus Biosciences Inc. Ms. Liu obtained her MPA in International Finance from the University of Southern California and her B.A. from the University of California, Berkeley.

Dr. Russell Medford is a Managing Partner of the Salutramed Group, LLC and has extensive private and public company expertise. He is also currently the CEO of healthEgames, Inc., a digital healthcare company and serves as the Executive Chairman of ViaMune, Inc., which is developing new immuno-oncology therapies. Dr. Medford has served as the co-founder, President, CEO and Director of AtheroGenics, Inc. and was a founding board member of Inhibitex, Inc. serving on its board until its acquisition by Bristol-Myers-Squibb in 2012. He has led companies through multiple stages of therapeutic drug R&D developing novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis. Dr. Medford obtained his M.D. and Ph.D. from the Albert Einstein College of Medicine.

“We are very pleased to have Vivian join the Cesca leadership team. Vivian has been a board member since November and with her diverse corporate finance and operations experience, the board is enthusiastic to have her take a much more involved role in the Company’s operations.” commented Dr. Xiaochun “Chris” Xu, Cesca’s Interim CEO. “Dr. Medford, who has a deep knowledge of drug development and clinical trials, will be of great value to the company as we continue to evaluate our clinical pipeline and prepare for our phase III trial in critical limb ischemia. We look forward to working with both Vivian and Dr. Medford to help position Cesca as a leader in the broader healthcare industry.”

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:

The SurgWerks™ System (in development) – a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.
The CellWerks™ System (in development) – a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.
The AutoXpress® System (AXP^®) – a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.
The MarrowXpress™ System (MXP™) – a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.
The BioArchive® System – an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
Manual bag sets for use in the processing and cryogenic storage of cord blood.

Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption “Risk Factors” in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

/EIN News/ —

Company Contact: Cesca Therapeutics Inc. 
                    ir@cescatherapeutics.com
                    
                    Investor Contact: The Ruth Group 
                    Lee Roth / Tram Bui 
                    646-536-7012 / 7035 
                    lroth@theruthgroup.com / tbui@theruthgroup.com

Month: March 2017